Navigation Links
Pharmos Corporation Reports 2008 First Quarter Results
Date:5/8/2008

ISELIN, N.J., May 8 /PRNewswire-FirstCall/ -- Pharmos Corporation (Nasdaq: PARS) today reported results for the first quarter ended March 31, 2008. The Company recorded a net loss of $3.6 million, or $0.14 per share, for the first quarter 2008 compared to a net loss of $4.8 million, or $0.19 per share, in the first quarter 2007. Cash and short-term investments totaled $11.3 million at March 31, 2008.

The decrease in net loss for the first quarter 2008 is due primarily to a 29% decrease in operating expenses, which was driven by a 68% decrease in general and administrative expenses to $0.8 million compared to $2.5 million in the first quarter 2007.

Research & development net, increased by $208,136 or 8%, from $2,570,098 in 2007 to $2,778,234 in 2008. Increased expenditures for the dextofisopam clinical trial are offset in part by the cost savings resulting from the downsizing and curtailment of general R&D programs. CB2 research and discovery and R&D overhead at our Rehovot facility were the areas of reduced spending.

During the first quarter, the Company advanced a Phase IIb trial of its lead compound, dextofisopam, in female IBS patients, which is expected to enroll approximately 480 patients in about 70 sites over an 18 month period. Costs of $2.0 million were incurred during the quarter in connection with the trial, comprising CRO-related activities and patient recruitment costs. Dextofisopam was one of the compounds the Company obtained through the acquisition of Vela Pharmaceuticals Inc. which closed in October 2006. The continued development of this compound through late-stage clinical testing will significantly increase the research and development expenses going forward.

A Phase 2a clinical trial with t
'/>"/>

SOURCE Pharmos Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Pharmos Issues Letter to Shareholders
2. Pharmos Corporation Reports 2007 Third Quarter Results
3. Pharmos Corporation to Present at the 2007 RBC Capital Markets Healthcare Conference
4. Pharmos Corporation Announces President & COO Alan L. Rubino to Leave Company
5. Pharmos Corporation Announces Board and Management Changes
6. Pharmos Corporation Completes Initial Closing of Private Placement
7. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. BioElectronics Corporation Announces Singapore and Malaysia Sales
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... , July 28, 2014  David Hardison, Ph.D., ... by Deloitte , has been elected chairman of ... Consortium, a non-profit working to establish common protocols ... as it relates to electronic health records. ... mission of collaborating with organizations across the research ...
(Date:7/28/2014)... Washington, DC (PRWEB) July 28, 2014 It’s ... their GI Bill benefits to further their post-secondary education are ... says a study released this year. And according to an ... of this shortfall is veteran students’ uninformed choice of college ... , The details of the study: Some 51.7 percent of ...
(Date:7/28/2014)... 2014 Research and Markets has announced ... 2014-2018" report to their offering. ... a technique used to determine the size of a particle ... crucial to analyze the size of particles as it can ... is performed to determine the behavior and nature of a ...
(Date:7/25/2014)... , July 25, 2014 Amgen (NASDAQ: ... Directors today declared a $0.61 per share dividend for ... paid on Sept. 5, 2014, to all stockholders of ... 14, 2014.  About Amgen Amgen is ... suffering from serious illnesses by discovering, developing, manufacturing and ...
Breaking Biology Technology:ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 3Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 2Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 3Resume Place: To Choose the Best College Majors, Veterans Need Early Career Counseling, Data Shows 4Global Particle Size Analysis Market 2014-2018 2Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3
... DIEGO, Dec. 12 Arena Pharmaceuticals,Inc. (Nasdaq: ... and Randall,E. Woods were appointed to its board ... seventh and eighth independent directors and bring,significant financial ... board of directors. Arena,s board also appointed Mr.,Schneider ...
... maintain successful partnerships, patient, recruitment expertise and its ... CINCINNATI, Dec. 12 Kendle (Nasdaq: KNDL ... today,announced it was named "Best CRO" at the ... selected from among leading global CROs by a,distinguished ...
... 12 The Center for Molecular,Medicine (CMM) today announced ... to offer a new test to help guide the ... or "advanced")., The CMM (http://www.cmmdx.org ) is ... physicians as a vital new tool in managing,patients with ...
Cached Biology Technology:Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors 2Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors 3Kendle Named Best CRO for Second Consecutive Year by Leading Global Pharmaceutical Publication Scrip 2Center for Molecular Medicine Among First Labs in Nation to Offer Groundbreaking Test to Aid in Treatment of Colorectal Cancer 2
(Date:7/28/2014)... (July 28, 2014) Rice University researchers are using ... varying flexibility that can be used as microscale models ... that "bead-spring" polymers, introduced as theory in the 1950s, ... required and should be of interest to materials scientists ... work led by Rice chemical and biomolecular engineer Sibani ...
(Date:7/28/2014)... prevent and treat HIV infection has been problematic until ... can arouse as they get rid of the invaders. ... Institute and the National Institutes of Health (NIH) have ... interferons around the time of infection could have ... research appeared in Nature . , Interferons, ...
(Date:7/28/2014)... explorer Roald Amundsen became the first man to reach ... 100 years later, an international team of scientists led ... have proven that air pollution from industrial activities arrived ... collected from widely spaced locations around the Antarctic continent, ... accurate and precise reconstruction to date of lead pollution ...
Breaking Biology News(10 mins):Seeing is bead-lieving 2Interfering with interferon 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 2Industrial lead pollution beat explorers to the South Pole by 22 years and persists today 3
... Climate change is causing higher air and water temperatures ... have shrunk the geographic region where blue mussels are able ... researchers published in the Journal of Biogeography . ... live along the East Coast as far south as Cape ...
... Einstein College of Medicine of Yeshiva University has been named ... Centers of Excellence in the Basic Biology of Aging. The ... pursuit of basic research into the biology of aging. Einstein,s ... National Institute on Aging. "Einstein has become a leader ...
... A newly formed advisory committee will develop ... environmental and genetic factors related to breast cancer. ... Coordinating Committee (IBCERCC) was established by the National ... with the National Cancer Institute (NCI), to review ...
Cached Biology News:Too hot to handle: Impacts of climate change on mussels 2Einstein designated an NIH Center of Excellence for aging research 2Einstein designated an NIH Center of Excellence for aging research 3Einstein designated an NIH Center of Excellence for aging research 4New breast cancer committee to establish federal research agenda 2New breast cancer committee to establish federal research agenda 3
Human RELT/TNFRSF19L MAb (Clone 238104)...
...
... assay kit measures NOS activity by monitoring ... This assay is simple, sensitive, and specific ... with both crude and purified enzyme preparations. ... for 50 total reactions. Radiolabeled arginine and ...
Human TSLP MAb (Clone 258136)...
Biology Products: